BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37024388)

  • 21. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
    Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies.
    Chang L; Li J; Zhang R
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188729. PubMed ID: 35436521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
    Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
    Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
    [No Abstract]   [Full Text] [Related]  

  • 25. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications.
    Bertoli E; De Carlo E; Basile D; Zara D; Stanzione B; Schiappacassi M; Del Conte A; Spina M; Bearz A
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC).
    Sardarabadi P; Kojabad AA; Jafari D; Liu CH
    Biosensors (Basel); 2021 Oct; 11(10):. PubMed ID: 34677350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
    Lu J; Han B
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818801809. PubMed ID: 30244652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021.
    Pisapia P; Costa JL; Pepe F; Russo G; Gragnano G; Russo A; Iaccarino A; de Miguel-Perez D; Serrano MJ; Denninghoff V; Quagliata L; Rolfo C; Malapelle U
    Crit Rev Oncol Hematol; 2021 May; 161():103311. PubMed ID: 33781866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
    Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
    Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
    Cirillo M; Craig AFM; Borchmann S; Kurtz DM
    Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid Biopsy - Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer.
    Raycheva GA; Ivanov HY; Grudeva-Popova ZG
    Folia Med (Plovdiv); 2021 Dec; 63(6):839-846. PubMed ID: 35851241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
    Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
    PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.
    Zhang YC; Zhou Q; Wu YL
    J Hematol Oncol; 2017 Oct; 10(1):167. PubMed ID: 29061113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
    Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
    Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.